Literature DB >> 11380418

Apoptosis and megakaryocytic differentiation during ex vivo expansion of human cord blood CD34+ cells using thrombopoietin.

K H Ryu1, S Chun, S Carbonierre, S A Im, H L Kim, M H Shin, H Y Shin, H S Ahn, S Y Woo, J Y Seoh, J K Fraser.   

Abstract

Thrombopoietin (TPO), the primary regulator of megakaryocytopoiesis, plays important roles in early haematopoiesis. Previously, we have demonstrated that TPO induces a characteristic pattern of apoptosis during ex vivo expansion of cord blood (CB) CD34+ cells. In this study, we have demonstrated that the TPO-induced apoptotic cells belong to the megakaryocytic (MK) lineage and that initially expanding MK progenitors declined along with the appearance of TPO-induced apoptosis. Human CB CD34+ cells were expanded in serum-free conditions with TPO. Multidimensional flow cytometry using simultaneous measurement of apoptosis and immunophenotyping showed that the TPO-induced apoptotic cells appeared in CD61+ fractions. Immunocytochemical analysis of the fluorescent activated cell-sorted fractions showed that the apoptosis-associated CD44low fraction expressed CD61. Clonogenic assay revealed 7.4 +/- 0.50-fold increase of total megakaryocyte colony-forming units (CFU-MKs) during the initial 9 d. Thereafter, the number of CFU-MKs decreased in parallel with the increase of apoptosis. When the MK colonies were subdivided according to size, the proportion of large colonies progressively decreased, while that of medium and small colonies increased. In particular, from d 6 small colonies became predominant. These results suggested that the MK progenitors matured as they expanded during ex vivo expansion with TPO and then proceeded to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380418     DOI: 10.1046/j.1365-2141.2001.02762.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  The end is just the beginning: megakaryocyte apoptosis and platelet release.

Authors:  J Li; D J Kuter
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

2.  Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.

Authors:  Danuta Jarocha; Karen K Vo; Randolph B Lyde; Vincent Hayes; Rodney M Camire; Mortimer Poncz
Journal:  Blood Adv       Date:  2018-03-27

3.  Three-Dimension Co-culture of Hematopoietic Stem Cells and Differentiated Osteoblasts on Gallic Acid Grafted-Chitosan Scaffold as a Model of Hematopoietic Stem Cells Niche.

Authors:  Jin Wang; Minghao Xiong; Qihao Sun; Wen-Song Tan; Haibo Cai
Journal:  Stem Cell Rev Rep       Date:  2022-01-05       Impact factor: 5.739

4.  Mechanistic studies on the effects of nicotinamide on megakaryocytic polyploidization and the roles of NAD+ levels and SIRT inhibition.

Authors:  Lisa M Giammona; Swapna Panuganti; Jan M Kemper; Pani A Apostolidis; Stephan Lindsey; Eleftherios T Papoutsakis; William M Miller
Journal:  Exp Hematol       Date:  2009-08-26       Impact factor: 3.084

5.  In vitro generation of functional dendritic cells from human umbilical cord blood CD34+ cells by a 2-step culture method.

Authors:  Kyung Ha Ryu; Su Jin Cho; Yoon Jae Jung; Ju Young Seoh; Jeong Hae Kie; Sang Hyeok Koh; Hyoung Jin Kang; Hyo Seop Ahn; Hee Young Shin
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

6.  Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia.

Authors:  Ai Gao; Yuemin Gong; Caiying Zhu; Wanzhu Yang; Qing Li; Mei Zhao; Shihui Ma; Jianyong Li; Sha Hao; Hui Cheng; Tao Cheng
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

7.  A systems-biology analysis of isogenic megakaryocytic and granulocytic cultures identifies new molecular components of megakaryocytic apoptosis.

Authors:  Chi Chen; Peter G Fuhrken; Li Ting Huang; Pani Apostolidis; Min Wang; Carlos J Paredes; William M Miller; Eleftherios T Papoutsakis
Journal:  BMC Genomics       Date:  2007-10-22       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.